XML 16 R4.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating Expenses:    
Research and development $ 2,602 $ 3,241
General and administrative 3,245 3,360
Total operating expenses 5,847 6,601
Operating loss (5,847) (6,601)
Other income (expense):    
Investment income, net 266 589
Other expense, net (105) (187)
Total other income 161 402
Net loss before benefit from income taxes and noncontrolling interests (5,686) (6,199)
Benefit from income taxes (962) (798)
Net loss (4,724) (5,401)
Less - net income (loss) attributable to noncontrolling interests 0 0
Net loss attributable to Lisata Therapeutics, Inc. common stockholders $ (4,724) $ (5,401)
Basic and diluted loss per share    
Lisata Therapeutics, Inc. common stockholders- basic (in usd per share) $ (0.55) $ (0.65)
Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share) $ (0.55) $ (0.65)
Weighted average common shares outstanding    
Basic shares (in shares) 8,602 8,294
Diluted shares (in shares) 8,602 8,294